Tesofensine is a small-molecule drug — not a peptide — that blocks the brain's reuptake of dopamine, noradrenaline, and serotonin all at once. In one phase 2 trial it produced some of the largest weight losses ever reported for a single obesity drug candidate1 — but a stimulant-like effect on the heart has shadowed it ever since, and it has never been approved as a standalone medicine.
In plain terms: it turns up three of the brain's appetite-and-reward signals, people eat less and lose weight — and the same switch also speeds the heart, which is the whole story of why it stalled.
A repurposed brain drug
Tesofensine did not start as an obesity drug. It was first developed for Alzheimer's and Parkinson's disease, where boosting brain monoamines was meant to help cognition and movement. Those programs disappointed on their primary goals, but one side effect was consistent: patients lost weight. That observation redirected the whole compound toward obesity.
How it works
Tesofensine is a triple monoamine reuptake inhibitor: nerve cells signal by releasing dopamine, noradrenaline, and serotonin and then reabsorbing them, and tesofensine blocks that reabsorption so all three stay elevated in the circuits that control appetite and reward4. The dopamine arm is the most revealing. Obese patients tend to have reduced central dopamine activity, which is thought to drive compensatory overeating; in diet-induced obese rats, tesofensine restored striatal dopamine D2/D3 receptor availability toward normal2 and indirectly strengthened dopamine signalling after blocking the dopamine transporter4. A 2024 study pinned part of the effect on GABAergic neurons in the lateral hypothalamus and found — tellingly — that tesofensine caused greater weight loss in obese animals than lean ones7.
Blocking three monoamines rather than one is deliberate. Serotonin drives satiety, noradrenaline curbs food intake, and dopamine governs food reward — so hitting all three aims for a broader appetite effect than the single-target serotonergic diet drugs that came before it. That history matters: several of those earlier serotonergic agents, such as fenfluramine, were ultimately withdrawn over heart-valve and cardiovascular problems8. Tesofensine does not carry that specific valve risk, but — as its own trials would show — it did not escape the broader cardiovascular scrutiny the whole appetite-suppressant class attracts.
The human evidence
The headline human trial is TIPO-1: a 24-week, phase 2, randomised, double-blind, placebo-controlled study of 203 obese patients across five Danish centres, all on an energy-restricted diet1.
| Group (24 weeks, with diet) | Mean weight loss |
|---|---|
| Placebo | 2.0% |
| Tesofensine 0.25 mg | 4.5% |
| Tesofensine 0.5 mg | 9.2% |
| Tesofensine 1.0 mg | 10.6% |
All three doses beat placebo (p < 0.0001), and the authors concluded the 0.5 mg dose "might have the potential to produce a weight loss twice that of currently approved drugs" — while stressing the result needed confirmation1. A separate human study found the appetite suppression was sustained rather than fading over time, which is not a given for appetite drugs3.
The catch that defines it: the heart
The mechanism that suppresses appetite is sympathomimetic — it stimulates the same "fight or flight" system that raises heart rate and blood pressure5. That showed up directly in TIPO-1: the 0.5 mg dose raised heart rate by 7.4 beats per minute, alongside dry mouth, nausea, constipation, and insomnia1. This is the recurring problem with centrally-acting appetite suppressants as a class, several of which have been withdrawn over cardiovascular or psychiatric safety6.
But the same rat research that mapped the cardiovascular effect also pointed to a fix: adding an anti-hypertensive preserved the appetite suppression while blunting the heart-rate and blood-pressure rise5.
Where it went: Tesomet
That fix became the development strategy. Tesofensine's more recent human work uses Tesomet — tesofensine combined with the beta-blocker metoprolol, specifically to counter the heart-rate effect. A 2022 randomised, placebo-controlled trial tested Tesomet (0.5 mg tesofensine / 50 mg metoprolol) over 24 weeks in 21 adults with hypothalamic obesity, a severe, treatment-resistant form for which no drugs are approved6. That is where tesofensine's development now sits: as a combination, aimed at niche indications — not the standalone blockbuster the early numbers hinted at.
What the studies found
| Study | Model | Key result | Year |
|---|---|---|---|
| Astrup — TIPO-11 | Human RCT, n=203 | 9.2–10.6% weight loss at 0.5–1.0 mg vs 2.0% placebo; heart rate +7.4 bpm | 2008 |
| Gilbert3 | Human | Appetite suppression sustained, not tolerance-prone | 2012 |
| van de Giessen2 | Rat (obese) | Restored low striatal dopamine D2/D3 receptor availability | 2012 |
| Bentzen5 | Rat (telemetry) | Cardiovascular effects are sympathomimetic; an anti-hypertensive blunts them | 2013 |
| Huynh — Tesomet6 | Human RCT, n=21 | Tesofensine + metoprolol trialled in hypothalamic obesity (safety primary) | 2022 |
| Perez7 | Rodent | Silences GABAergic lateral-hypothalamus neurons; stronger in obese | 2024 |
How it compares
Tesofensine is a completely different kind of drug from the GLP-1 medicines that dominate obesity treatment today. Semaglutide and tirzepatide are peptides that mimic gut hormones and are delivered by injection; tesofensine is an oral small molecule acting on brain neurotransmitters. They are unrelated drug classes that happen to be studied for the same problem — and it is the GLP-1s, not tesofensine, that reached approval and scale.
Status and latest research
Tesofensine is not approved by the FDA or EMA. Its strongest standalone evidence remains the phase 2 TIPO-1 trial; active development has moved to the Tesomet combination in specific, hard-to-treat obesities6, while the newest mechanistic work continues to refine *where* in the brain it acts7. This is an educational overview, not medical advice.